Guo Li-min, Liu Jing-yuan, Xu Dao-zhen, Li Bao-shun, Han Hao, Wang Ling-hang, Zhang Wei-yan, Lu Lian-he, Guo Xia, Sun Feng-xia, Zhang Hong-yu, Liu Xiao-dong, Zhang Jian-ping, Yao Jun, He Zhong-ping, Wang Min-min
Infensive Care Unit or Artificial Liver Support Center, Beijing Ditan Hospital, Beijing 100011, China.
Zhonghua Gan Zang Bing Za Zhi. 2003 Aug;11(8):455-7.
To evaluate the effectiveness and mechanisms of molecular adsorbents recirculating system (MARS) treatment in severe liver failure patients with multiple organ dysfunction syndrome (MODS).
60 single MARS treatments were performed for 6 - 24 hours on 24 severe liver failure patients with MODS.
MARS therapy was associated with marked reduction of albumin bound toxins and water soluble toxins, together with a significant removal of NO and certain cytokines, such as TNF-alpha, IL-6, IL-8, and INF-gamma. These were associated with a improvement of the patients' clinical conditions including hepatic encephalopathy, deranged hemodynamic situation, as well as renal and respiratory function, thus resulted into marked decrease of sequential organ failure assessment (SOFA) score (from 9.72+-1.89 to 6.98+-2.34), and improving outcome: 9 patients were able to be discharged from the hospital or bridged to successful liver transplantation. The overall survival rate of 24 patients was 37.5%.
There is positive therapeutic impact and safety to use MARS on liver failure patients with MODS. The effectiveness of MARS is correlated with reducing the levels of NO and cytokines, except for completely removing of accumulated toxins in liver failure patients.
评估分子吸附再循环系统(MARS)治疗对伴有多器官功能障碍综合征(MODS)的严重肝衰竭患者的有效性及作用机制。
对24例伴有MODS的严重肝衰竭患者进行了60次MARS单次治疗,每次治疗6 - 24小时。
MARS治疗与白蛋白结合毒素和水溶性毒素的显著降低相关,同时能有效清除一氧化氮(NO)及某些细胞因子,如肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)和γ干扰素(INF-γ)。这些变化与患者临床状况的改善相关,包括肝性脑病、紊乱的血流动力学状态以及肾脏和呼吸功能的改善,从而使序贯器官衰竭评估(SOFA)评分显著降低(从9.72±1.89降至6.98±2.34),并改善了预后:9例患者得以出院或成功过渡到肝移植。24例患者的总生存率为37.5%。
对伴有MODS的肝衰竭患者使用MARS有积极的治疗作用且安全。MARS的有效性与降低NO和细胞因子水平相关,此外还能完全清除肝衰竭患者体内蓄积的毒素。